We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cancer-Detecting Nanoparticles Developed for MR Imaging

By Biotechdaily staff writers
Posted on 18 Jun 2008
Magnetic resonance imaging (MRI) can be an excellent tool for detecting a tumor in the body without resorting to surgery. More...
Now, a team of researchers has created the smallest magnetic nanoparticles to date that can be utilized on such seek-and-find missions. With a thinner coating, the particles also emit a stronger signal for the MRI to detect.

MRI scans use pulses of magnetic waves, and gauge the return signals to identify different types of tissue in the body, such as telling bone from muscle, or fluids from solids. Scientists have found that magnetic nanoparticles can be especially helpful in locating cancerous cell clusters during MRI scans. Like tiny guided missiles, the nanoparticles seek out tumor cells and attach themselves to them. Once the nanoparticles attach themselves to these cancer cells, the particles operate like radio transmitters, greatly aiding the MRI's detection capability.

The study's findings have been published online in May 26, 2008, in the Journal of the American Chemical Society. The research was performed by Brown University chemist Dr. Shouheng Sun and a team of researchers from Brown University (Providence, RI, USA). The graduates students, included Jin Xie, Chenjie Xu, and Sheng Peng, collaborated on the research, along with Professor Xiaoyuan Chen and his associates from Stanford University (Stanford, CA, USA).

The team created peptide-coated iron oxide nanoparticles--particles billionths of a meter in size. The researchers injected the particles into mice and assessed their ability to locate a brain tumor cell called U87MG. Dr. Sun and his coworkers concentrated specifically on the nanoparticle's size and the thickness of the peptide coating, which ensures the nanoparticle attaches to the tumor cell.

Size is important because the trick is to create a nanoparticle that is small enough to navigate through the bloodstream and reach the diseased area. Bigger particles tend to stack up, creating the circulatory system's version of a traffic jam. Dr. Sun's team developed a nanoparticle that is about 8.4 nm in overall diameter--some six times smaller than the size of particles currently used in medicinal procedures.

"We wanted to make [the nanoparticle] very small, so the body's immune system won't recognize it,” Dr. Sun explained. "That way, you let more particles interact with and attach to the tumor cell.”

Nanoparticles are important in MRI detection because they enhance what scientists refer to as the contrast between the background, such as water molecules in the body, and a solid mass, such as a tumor. The coating, while integral to the nanoparticles' attachment to the tumor cell, also is crucial to establishing the signal-to-noise ratio that an MRI uses: the thinner the coating, the stronger the emitted signal and vice versa. Dr. Sun's team outfitted their nanoparticles with a two-nm thick peptide coating--10 times thinner than the coating available in popular MRI contrast agents such as Feridex. (Feridex's generic name is ferumoxides, and is manufactured by Amag Pharmaceuticals [Cambridge, MA, USA] and is sold in the United States by Bayer Healthcare Pharmaceuticals [Wayne, NJ, USA].)

Dr. Sun's nanoparticles are similar to having a 50,000-watt radio transmitter versus a 150-watt station; it is easier for the MRI to "hear” the stronger signal and to hone in on the signal's source. Another key feature of the team's research is discovering that the RGD peptide coating binds nearly seamlessly to the U87MG tumor cell.

The team plans to test the particle's ability to bind with other tumor cells in further animal studies.


Related Links:
Brown University

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.